Journal for ImmunoTherapy of Cancer · 2013 · 19 citations · 0 references
MedicinePharmacologyCancer PharmacologyImmunopharmacologyTumor ImmunologyAntitumor T Cell ResponsesCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmune Checkpoint RegulationImmune CheckpointsCheckpoint Antagonist TherapyCheckpoint Inhibitor AntibodiesDurable Clinical ResponseImmune Checkpoint Inhibitor TherapyImmune Checkpoint LigandsImmune-mediated Adverse Events
Meeting abstracts Recent advances in achieving highly durable clinical responses via inhibition of immune checkpoint proteins including CTLA-4 and PD1 have revolutionized the outlook for cancer therapy. However, along with impressive clinical activity (response rate of ~25% with either anti-CTLA-4